These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 16476694

  • 1. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
    Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.
    Eur Heart J; 2006 May; 27(9):1038-47. PubMed ID: 16476694
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
    Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, DISPERSE-2 Investigators.
    J Am Coll Cardiol; 2007 Nov 06; 50(19):1844-51. PubMed ID: 17980250
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP.
    J Am Coll Cardiol; 2007 Nov 06; 50(19):1852-6. PubMed ID: 17980251
    [Abstract] [Full Text] [Related]

  • 4. The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.
    Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.
    Platelets; 2011 Nov 06; 22(7):495-503. PubMed ID: 21526889
    [Abstract] [Full Text] [Related]

  • 5. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL, Malinin AI, Pokov AN, Hanley DF.
    Clin Ther; 2008 Feb 06; 30(2):249-59. PubMed ID: 18343263
    [Abstract] [Full Text] [Related]

  • 6. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
    Husted S, Harrington RA, Cannon CP, Storey RF, Mitchell P, Emanuelsson H.
    Int J Clin Pract; 2009 Apr 06; 63(4):667-70. PubMed ID: 19335707
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
    Teng R, Maya J, Butler K.
    Platelets; 2013 Apr 06; 24(8):615-24. PubMed ID: 23249161
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.
    Am Heart J; 2009 Apr 06; 157(4):599-605. PubMed ID: 19332184
    [Abstract] [Full Text] [Related]

  • 9. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
    Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R.
    Semin Thromb Hemost; 1999 Apr 06; 25 Suppl 2():9-14. PubMed ID: 10440416
    [Abstract] [Full Text] [Related]

  • 10. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF.
    Circulation; 2009 Dec 22; 120(25):2577-85. PubMed ID: 19923168
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
    Butler K, Teng R.
    Br J Clin Pharmacol; 2010 Jul 22; 70(1):65-77. PubMed ID: 20642549
    [Abstract] [Full Text] [Related]

  • 12. Single-dose pharmacodynamics of clopidogrel.
    Thebault JJ, Kieffer G, Cariou R.
    Semin Thromb Hemost; 1999 Jul 22; 25 Suppl 2():3-8. PubMed ID: 10440415
    [Abstract] [Full Text] [Related]

  • 13. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R.
    Semin Thromb Hemost; 1999 Jul 22; 25 Suppl 2():15-9. PubMed ID: 10440417
    [Abstract] [Full Text] [Related]

  • 14. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S, Roe MT.
    Cardiovasc Drug Rev; 2007 Jul 22; 25(2):188-203. PubMed ID: 17614940
    [Abstract] [Full Text] [Related]

  • 15. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
    Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA, ONSET/OFFSET Investigators.
    J Am Coll Cardiol; 2010 Jul 13; 56(3):185-93. PubMed ID: 20620737
    [Abstract] [Full Text] [Related]

  • 16. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis.
    Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J.
    Semin Thromb Hemost; 1999 Jul 13; 25 Suppl 2():41-5. PubMed ID: 10440422
    [Abstract] [Full Text] [Related]

  • 17. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA, Payne CD, Weerakkody GJ, Brandt JT, Farid NA, Li YG, Naganuma H, Lachno DR, Winters KJ.
    J Cardiovasc Pharmacol; 2007 Mar 13; 49(3):167-73. PubMed ID: 17414229
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
    Anderson SD, Shah NK, Yim J, Epstein BJ.
    Ann Pharmacother; 2010 Mar 13; 44(3):524-37. PubMed ID: 20124464
    [Abstract] [Full Text] [Related]

  • 19. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
    Small DS, Farid NA, Li YG, Ernest CS, Payne CD, Salazar DE, Winters KJ.
    Curr Med Res Opin; 2008 Aug 13; 24(8):2251-7. PubMed ID: 18786302
    [Abstract] [Full Text] [Related]

  • 20. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
    Payne CD, Li YG, Small DS, Ernest CS, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.
    J Cardiovasc Pharmacol; 2007 Nov 13; 50(5):555-62. PubMed ID: 18030066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.